Last updated: September 14, 2026
Tildrakizumab-asmn, marketed as Ilumya in the United States and Ilumetri in Europe, is an interleukin-23p19 monoclonal antibody used to treat moderate-to-severe plaque psoriasis. Sun Pharmaceutical Industries owns the primary commercial rights in the United States, while Almirall commercializes the product in Europe under a regional licensing arrangement.
The product has a durable commercial profile because it combines a maintenance schedule of one injection every 12 weeks after induction with established efficacy and a biologic market that continues to expand. Its main constraints are intense competition from IL-17 and IL-23 biologics, relatively limited approved indications, payer pressure, and the eventual development of biosimilar competition.
Sun Pharma does not publicly report Ilumya revenue as a separate audited line item. Public financial disclosures report broader specialty, innovative-medicine, or dermatology categories. This limits molecule-level revenue precision, but available company disclosures indicate that Ilumya is a material contributor to Sun Pharma’s specialty portfolio and Almirall’s dermatology business.
What is tildrakizumab-asmn and how is Ilumya used?
Tildrakizumab-asmn is a humanized IgG1/kappa monoclonal antibody that selectively binds the p19 subunit of interleukin-23. Blocking IL-23 reduces inflammatory signaling implicated in plaque psoriasis.
The FDA approved Ilumya on March 20, 2018, for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dose is 100 mg by subcutaneous injection at weeks 0 and 4, followed by administration every 12 weeks.[1]
| Product |
Active ingredient |
Primary indication |
Dose schedule |
U.S. sponsor |
| Ilumya |
Tildrakizumab-asmn |
Moderate-to-severe plaque psoriasis |
Weeks 0 and 4, then every 12 weeks |
Sun Pharmaceutical Industries |
| Ilumetri |
Tildrakizumab |
Moderate-to-severe plaque psoriasis |
Weeks 0 and 4, then every 12 weeks |
Almirall in Europe |
The quarterly maintenance schedule is commercially important. It is less frequent than many older biologic regimens and can support persistence, office-based administration, and patient convenience. Its clinical differentiation is narrower than that of competitors with multiple approved inflammatory or immune-mediated indications.
How large is the tildrakizumab-asmn market?
The addressable market is the global moderate-to-severe plaque psoriasis biologic market, which is one of the largest specialty pharmaceutical segments. The market includes tumor necrosis factor inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23p19 inhibitors, oral immunomodulators, and newer targeted therapies.
The commercial market has shifted toward selective IL-23p19 inhibitors. The leading products include:
| Product |
Molecule |
Company |
Mechanism |
Key commercial advantage |
| Skyrizi |
Risankizumab-rzaa |
AbbVie |
IL-23p19 |
Strong efficacy, multiple indications |
| Tremfya |
Guselkumab |
Johnson & Johnson |
IL-23p19 |
Broadening indications and established franchise |
| Ilumya |
Tildrakizumab-asmn |
Sun Pharma |
IL-23p19 |
Quarterly maintenance dosing |
| Sotyktu |
Deucravacitinib |
Bristol Myers Squibb |
TYK2 inhibitor |
Oral administration |
| Cosentyx |
Secukinumab |
Novartis |
IL-17A |
Broad immunology footprint |
| Taltz |
Ixekizumab |
Eli Lilly |
IL-17A |
High-efficacy injectable biologic |
| Stelara |
Ustekinumab |
Johnson & Johnson |
IL-12/23 |
Large historical franchise and broad indications |
Ilumya entered after Stelara, Cosentyx, and Taltz had established strong prescriber relationships. It also competes against Skyrizi and Tremfya, which have achieved greater commercial scale and broader label expansion.
What drives demand for Ilumya?
Demand is influenced by five factors:
- Clinical efficacy and safety in plaque psoriasis.
- Twelve-week maintenance dosing.
- Payer formulary placement and rebate economics.
- Prescriber familiarity with IL-23 therapy.
- Expansion of specialty pharmacy and office-administered biologic channels.
The product’s dosing advantage is real but insufficient by itself to overcome a narrower label. Skyrizi and Tremfya have expanded into psoriatic arthritis, inflammatory bowel disease, and other conditions. Ilumya remains primarily concentrated in plaque psoriasis.
What is the financial trajectory of tildrakizumab-asmn?
Ilumya has progressed from launch-stage investment to a mature specialty product with continued growth potential. Sun Pharma acquired the product from Merck in 2016 before U.S. approval, giving Sun control over commercialization and development in the U.S. market.[2]
Sun Pharma reports Ilumya within broader specialty or innovative-medicine disclosures rather than as a consistently separate global revenue line. Almirall likewise reports its business through dermatology and regional product categories. As a result, the public record supports directional analysis rather than a fully reconciled global Ilumya income statement.
Sun Pharma’s financial exposure
Ilumya is strategically important to Sun Pharma’s specialty portfolio, but it is not the company’s largest specialty asset. Sun’s specialty platform includes products such as Winlevi, Cequa, Odomzo, and other branded medicines. Sun’s consolidated revenue base is diversified across India, the United States, emerging markets, and specialty products.[3]
The financial trajectory can be characterized as follows:
| Period |
Financial phase |
Commercial interpretation |
| 2018-2019 |
Launch |
Initial market access, physician adoption, and promotional investment |
| 2020-2021 |
Expansion |
Greater payer coverage and increased use of quarterly maintenance dosing |
| 2022-2023 |
Scaling |
More established specialty contribution, but greater competition from IL-23 peers |
| 2024 onward |
Maturity and defense |
Growth depends on share retention, payer positioning, and new indication potential |
Sun Pharma’s earnings sensitivity to Ilumya is meaningful but limited relative to total company revenue. The product is more important as a recurring specialty-growth asset than as a company-defining revenue concentration.
Almirall’s financial exposure
Almirall commercializes Ilumetri in Europe under a licensing arrangement with Sun Pharma. The product is included within Almirall’s dermatology portfolio, alongside medicines such as Ilumetri, Ebglyss, Wynzora, Klisyri, and other dermatology products depending on market and reporting period.[4]
Almirall’s economics depend on European uptake, pricing, reimbursement, and royalty or transfer arrangements. European net pricing is generally more constrained than U.S. pricing, but the region offers a large established psoriasis market and lower commercial infrastructure requirements when a product is distributed through a regional dermatology platform.
How does Ilumya compare with Skyrizi and Tremfya?
Ilumya’s direct competitive weakness is not its mechanism. It operates in the same IL-23p19 class as Skyrizi and Tremfya. The difference is franchise breadth and commercial scale.
| Factor |
Ilumya |
Skyrizi |
Tremfya |
| Target |
IL-23p19 |
IL-23p19 |
IL-23p19 |
| Psoriasis dosing |
Every 12 weeks after induction |
Every 12 weeks after induction |
Every 8 weeks after induction in psoriasis |
| Major franchise breadth |
Primarily psoriasis |
Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis |
Psoriasis, psoriatic arthritis, inflammatory bowel disease expansion |
| Corporate scale |
Sun Pharma |
AbbVie |
Johnson & Johnson |
| Commercial position |
Specialist psoriasis product |
Global immunology franchise |
Global immunology franchise |
| Main risk |
Limited indications and payer competition |
Patent and biosimilar exposure over time |
Patent and biosimilar exposure over time |
Skyrizi’s multiple indications create a larger prescriber base and permit broader commercial investment. Tremfya benefits from Johnson & Johnson’s global immunology infrastructure. Ilumya must compete mainly within psoriasis, where payer controls and treatment sequencing can determine market share.
What patents protect tildrakizumab-asmn?
Tildrakizumab is protected primarily through biologic composition-of-matter, antibody, manufacturing, formulation, and use-related intellectual property. Because Ilumya is licensed as a biologic under the Public Health Service Act, its patent profile should be assessed through FDA Purple Book information, USPTO records, issued patent families, licensing agreements, and litigation databases rather than through a conventional small-molecule Orange Book analysis.
What is the Orange Book status of Ilumya?
Ilumya is not evaluated through the ordinary small-molecule generic-substitution framework. The FDA’s Orange Book is principally used for approved drug products and listed patents associated with abbreviated new drug applications. Biosimilar competition for tildrakizumab would proceed under the Biologics Price Competition and Innovation Act through a 351(k) application and Purple Book reference-product framework.[5]
The relevant regulatory exclusivity period for a reference biologic is 12 years from first licensure, subject to statutory rules and exclusivity calculations. For Ilumya, the reference-product exclusivity period is generally assessed from its March 2018 U.S. licensure date, while patent expiry dates depend on individual patent families and any patent-term adjustments or extensions.
What patent barriers affect biosimilar entry?
A tildrakizumab biosimilar entrant could face several barriers:
- High-complexity analytical and clinical comparability requirements.
- Manufacturing process knowledge protected as trade secrets.
- Cell-line and purification-process control.
- Patent disputes over antibody sequences, formulations, dosing, and manufacturing.
- Physician and payer switching resistance.
- Contracting and specialty-pharmacy access requirements.
The most valuable protection is likely the combination of biologic manufacturing know-how and patent coverage rather than any single formulation claim. Even after core patent expiry, biosimilar entry may require substantial investment and may not produce immediate substitution because biologics do not automatically receive small-molecule-style pharmacy substitution.
When does tildrakizumab-asmn lose exclusivity?
The product’s statutory biologic exclusivity is tied to its 2018 U.S. licensure. A 351(k) biosimilar applicant generally cannot obtain approval before the statutory 12-year reference-product exclusivity period has elapsed, although patent litigation and filing timelines can begin earlier under the BPCIA framework.[5]
The practical loss-of-exclusivity date is therefore determined by three separate events:
| Exclusivity component |
Relevance |
| FDA reference-product exclusivity |
Limits approval of a biosimilar before the statutory period ends |
| Patent expiry |
Determines whether commercial launch can occur without infringement exposure |
| Litigation or settlement |
May move the effective launch date after approval |
| Manufacturing readiness |
Determines whether an approved biosimilar can scale supply |
| Market adoption |
Determines the speed of erosion after launch |
A precise single launch date cannot be inferred solely from the FDA approval date. A commercial biosimilar may launch after reference exclusivity but before every potentially relevant patent has expired if the entrant reaches a settlement or accepts litigation risk.
Are there Paragraph IV challenges to Ilumya?
Paragraph IV certification is a Hatch-Waxman mechanism for small-molecule abbreviated new drug applications. Ilumya is a biologic, so a conventional Paragraph IV generic challenge is not the primary pathway.
A future competitor would more likely use the BPCIA biosimilar pathway. The relevant dispute would involve patent-listing exchanges, the so-called patent dance, declaratory actions, infringement litigation, and possible settlement. Publicly available information through the latest broadly reported period does not identify a commercially material Ilumya biosimilar litigation campaign comparable to major small-molecule Paragraph IV disputes.
What formulation and method-of-use patents protect Ilumya?
Biologic protection can extend beyond the antibody sequence. Relevant claim categories may include:
Formulation protection
Formulation claims can cover stabilizers, buffers, surfactants, concentration ranges, pH ranges, aggregation control, and storage conditions. These claims can make a biosimilar entrant design around the reference presentation, although a competing product may use a different formulation if it remains analytically and clinically comparable.
Method-of-use protection
Method-of-use claims may cover treatment of plaque psoriasis, patient subgroups, dosing schedules, induction regimens, maintenance administration, or combinations with other therapies. Their commercial value depends on claim scope, enforceability, and whether physicians can avoid the patented use.
Manufacturing protection
Manufacturing claims can cover cell culture conditions, purification, viral clearance, conjugation or processing steps, and product-quality attributes. Process patents and confidential know-how are important because antibody production must meet strict consistency and comparability standards.
What licensing deals shape the tildrakizumab market?
The central transaction is Sun Pharma’s acquisition of the tildrakizumab program from Merck in 2016. The transaction transferred commercial and development responsibility to Sun Pharma and positioned Sun to own the U.S. franchise.[2]
Sun Pharma separately entered into a European commercialization agreement with Almirall. Almirall obtained rights to develop and commercialize tildrakizumab in Europe, while Sun retained rights in other territories subject to regional arrangements.[4]
This structure creates a split commercial model:
- Sun Pharma controls the U.S. specialty franchise.
- Almirall leads European commercialization.
- Regional revenue and margin economics differ by market.
- Development decisions may require coordination between the partners.
- Product performance is exposed to two companies’ market-access execution.
What FDA regulatory status does Ilumya have?
Ilumya is FDA-approved for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is administered subcutaneously and is not approved as a biosimilar or interchangeable product.
The key regulatory limitation is the absence of a broad inflammatory-disease label comparable to major competitors. Label expansion into psoriatic arthritis or inflammatory bowel disease could increase the addressable market, but such expansion would require successful clinical development and FDA approval. The commercial return would depend on trial cost, development timing, payer coverage, and competitive intensity.
What generic and biosimilar entry risks exist?
Near-term erosion risk is lower than for a conventional small molecule because biologic entry requires a 351(k) development program and manufacturing infrastructure. Long-term erosion risk remains significant.
The primary scenarios are:
| Scenario |
Commercial effect |
| No biosimilar before late exclusivity |
Continued branded revenue growth or stability |
| One biosimilar launch |
Moderate price pressure and selective payer substitution |
| Multiple biosimilars |
Greater discounts, formulary displacement, and lower net sales |
| Settlement with delayed entry |
Extended branded revenue period |
| Label expansion before entry |
Larger revenue base but potentially greater post-entry exposure |
Sun Pharma’s ability to retain share will depend on contracting, patient-support programs, injection-device economics, supply reliability, and whether the product gains additional indications.
How strong is the tildrakizumab patent estate?
The estate is commercially meaningful but should not be treated as impenetrable. Biologic patent strength usually depends on claim breadth, written-description support, prosecution history, continuation strategy, and the ability to assert claims against a biosimilar manufacturing process.
Ilumya’s strongest protection is likely the combination of:
- Antibody and sequence-related claims.
- Product-by-process or manufacturing claims.
- Formulation and stability claims.
- Dosing and treatment-method claims.
- Confidential manufacturing know-how.
Its relative weakness is the possibility that a biosimilar entrant can design around narrower formulation or method-of-use claims while pursuing a separate manufacturing process. The commercial life of the product therefore depends on both patents and operational barriers.
What patent litigation affects tildrakizumab-asmn?
No widely reported, market-defining U.S. biosimilar litigation has materially altered Ilumya’s commercial timeline through the latest broadly available public disclosures. The more relevant future litigation risk would arise from a 351(k) applicant challenging composition, formulation, method-of-use, or manufacturing patents.
A meaningful dispute would likely be evaluated by:
- Patent claims identified in the Purple Book and related public records.
- BPCIA notice and patent-exchange events.
- District-court infringement complaints.
- Patent-term adjustments and extensions.
- Settlement restrictions and launch dates.
- Whether the biosimilar seeks approval for all or only selected indications.
What is the likely financial outlook for Ilumya?
The base case is sustained but moderate growth rather than explosive expansion. Ilumya has a durable dosing profile and a recognized IL-23 mechanism, but its revenue ceiling is constrained by a single major indication and stronger competitors with broader labels.
Bull case
Revenue grows through improved payer access, stronger U.S. dermatology adoption, European expansion, and an additional approved indication. Sun Pharma benefits from a larger specialty contribution without immediate biosimilar erosion.
Base case
Ilumya remains a stable specialty product. Growth comes from psoriasis treatment switching and patient retention, while payer discounts and competition limit net-price expansion. Sun Pharma continues to report the product as part of a broader specialty portfolio.
Bear case
Skyrizi and Tremfya continue to take share, newer oral therapies improve payer positioning, and a biosimilar entrant launches after reference exclusivity. Net sales decline faster than prescription volume because of rebates and price concessions.
The product is unlikely to create company-level concentration risk for Sun Pharma, but it remains relevant to the company’s margin mix because specialty biologics generally carry higher strategic value than commoditized generic products.
Key Takeaways
- Tildrakizumab-asmn is an IL-23p19 biologic marketed as Ilumya in the U.S. and Ilumetri in Europe.
- Sun Pharma owns the main U.S. commercial franchise; Almirall commercializes the product in Europe.
- The product’s quarterly maintenance schedule supports adherence and differentiation.
- Its main commercial limitation is a narrower indication set than Skyrizi and Tremfya.
- Sun Pharma and Almirall do not consistently disclose standalone global Ilumya revenue.
- Conventional Paragraph IV generic litigation does not apply because Ilumya is a biologic.
- Future competition would most likely arise through the BPCIA biosimilar pathway.
- Patent value extends across antibody, formulation, manufacturing, dosing, and method-of-use claims.
- The financial base case is durable specialty revenue with moderate growth and eventual biosimilar price pressure.
- The most important upside variable is label expansion; the main downside variables are payer competition and biosimilar entry.
FAQs About Tildrakizumab-asmn Market and Exclusivity
Who owns Ilumya in the United States?
Sun Pharmaceutical Industries owns and commercializes Ilumya in the United States after acquiring the tildrakizumab program from Merck.
Is Ilumya interchangeable with a biosimilar?
No. Ilumya is the reference biologic, and no interchangeable tildrakizumab biosimilar had materially entered the U.S. market through the latest broadly reported period.
How often is Ilumya administered?
Patients receive doses at weeks 0 and 4, followed by a maintenance injection every 12 weeks.
Does Ilumya treat psoriatic arthritis?
The core FDA-approved Ilumya indication is moderate-to-severe plaque psoriasis. It does not have the same broad psoriatic arthritis label as certain competing IL-23 products.
Is tildrakizumab a high-revenue biologic?
It is a commercially established specialty biologic, but its precise global revenue is not separately disclosed consistently by Sun Pharma or Almirall. Its financial importance is best assessed within each company’s specialty or dermatology portfolio.
References
- U.S. Food and Drug Administration. (2018). FDA approves new treatment for moderate-to-severe plaque psoriasis. https://www.fda.gov
- Merck & Co., Inc. (2016). Merck to sell investigational psoriasis medicine tildrakizumab to Sun Pharma. https://www.merck.com
- Sun Pharmaceutical Industries Limited. (2024). Annual report 2023-24. https://www.sunpharma.com
- Almirall, S.A. (2024). Annual report 2023. https://www.almirall.com
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
